Sage Journals: Discover world-class research

Abstract

Introduction

High-sodium intake blunts the renoprotective efficacy of angiotensin-converting enzyme (ACE) inhibitors. We investigated whether targeting the drug to the kidneys may attenuate the inferior response to ACE inhibitor (ACE-I) under high-sodium conditions. The ACE-I, captopril, was coupled to the low molecular weight protein (LMWP) lysozyme, yielding captopril-lysozyme conjugates that accumulate specifically in the proximal tubular cells of the kidneys.We compared the antiproteinuric efficacy of captopril to that of the captopril-lysozyme conjugate in adriamycin-induced proteinuric rats fed with a high-sodium diet.

Materials and methods

Rats with adriamycin (single injection 2 mg/kg)-induced proteinuria were put on a high-sodium diet (HS; 3% NaCl). When stable proteinuria developed at 5.5 weeks, animals were assigned to the following subcutaneous treatments: (1) vehicle (n=7); (2) lysozyme (equivalent to the amount in conjugate) (n=7); (3) captopril (5 mg/kg/24 hours) (n=8); (4) captopril-lysozyme conjugate (captopril content equivalent to 1mg captopril/kg/24 hours) (n=7). Blood pressure and proteinuria were monitored. After 10 days of treatment the rats were sacrificed and kidneys and plasma were removed.

Results

Results are given as mean + S.E.M. After injection with adriamycin at t=0, stable proteinuria developed, amounting to 547+79 mg/24 hours at week 5.5. Subsequently, after seven and nine days of treatment, no reduction of proteinuria was observed in the captopril-treated group. In contrast, a significant reduction in proteinuria, amounting to 35+4% (day seven) and 25+2% (day nine), was observed in the captopril-lysozyme conjugate group (p<0.05 compared with the captopril group). In contrast, blood pressure was reduced in the captopril-treated group by 13.9+2.9 mmHg, while in the captopril-lysozyme treated group, an increase of 7.9+3.3 mmHg was found. Renal ACE activity was lowered by 30% in the captopril, as well as in the captopril-lysozyme conjugate treated group, compared with control. Furthermore, the ratio of kidney: plasma levels of captopril almost doubled as a consequence of coupling to lysozyme.

Conclusion

In proteinuric rats fed with a high-sodium diet, captopril induced a reduction in blood pressure without an effect on proteinuria. In contrast, renal targeting of a five times lower dose of the ACE-I with the captopril-lysozyme conjugate reduced proteinuria without reducing blood pressure. Therefore, renal targeting of ACE-I may be a promising strategy to optimise the therapeutic response of ACE-I.

Keywords

ACE-inhibition renal targeting proteinuria low molecular weight protein lysozyme

Get full access to this article

View all access options for this article.

References

Navis G. , Faber HJ , de Zeeuw D. , de Jong PE ACE inhibitors and the kidney. A risk-benefit assessment. Drug Saf 1996;15: 200-11.

Pisoni R. , Faraone R. , Ruggenent P. , Remuzzi G. Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency . J Nephrol 2002;15:428-30.

Palla R. , Panichi V. , Finato V. et al. Effect of increasing doses of lisinopril on proteinuria of normotensive patients with IgA nephropathy and normal renal function. Int J Clin Pharmacol Res 1994;14:35-43.

Textor SC , Bravo EL , Fouad FM , Tarazi RC Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril. Am J Med 1982;73:719-25.

Heeg JE , de Jong PE , van der Hem GK , de Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989;36:272-9.

Buter H. , Hemmelder MH , Navis G. , de Jong PE , de Zeeuw D. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998;13:1682-5.

Kocks MJ , Buikema H. , Gschwend S. , Boomsma F. , de Zeeuw D. , Navis G. High dietary sodium blunts effects of angiotensin-converting enzyme inhibition on vascular angiotensin I-to-angiotensin II conversion in rats . J Cardiovasc Pharmacol 2003;42:601-06.

Laverman GD , Van Goor H. , Henning RH , de Jong PE , de Zeeuw D. , Navis G. Renoprotective effects of VPI versus ACEI in normotensive nephrotic rats on different sodium intakes. Kidney Int 2003;63:64-71.

Kok RJ , Grijpstra F. , Walthuis RB , Moolenaar F. , de Zeeuw D. , Meijer DK Specific delivery of captopril to the kidney with the prodrug captopril-lysozyme . J Pharmacol Exp Ther 1999;288: 281-5.

10.

Kok RJ , Haverdings RF , Grijpstra F. et al. Targeting of captopril to the kidney reduces renal angiotensin-converting enzyme activity without affecting systemic blood pressure. J Pharmacol Exp Ther 2002;301:1139-43.

11.

Kok RJ , Visser J. , Moolenaar F. , de Zeeuw D. , Meijer DK Bioanalysis of captopril: two sensitive high-performance liquid chromatographic methods with pre- or postcolumn fluorescent labeling.JChromatogr B Biomed Sci Appl 1997;693:181-9.

12.

Koiter J. , Navis G. , de Jong PE , Van Gilst WH , de Zeeuw D. Sample dilution: a methodological pitfall in the measurement of tissue but not serum ACE-activity. J Pharmacol Toxicol Methods 1998;39:45-9.

13.

Prakash J. , van Loenen-Weemaes AM , Haas M. et al. Renal-selective delivery and ACE inhibition by subcutaneously administered captopril-lysozyme. Drug Metab Dispos 2005 (Epub ahead of print).

14.

Ondetti MA , Cushman DW Inhibition of the renin-angiotensin system. A new approach to the therapy of hypertension. J Med Chem 1981;24:355-61.

15.

Franssen EJ , van Amsterdam RG , Visser J. , Moolenaar F. , de Zeeuw D. , Meijer DK Low molecular weight proteins as carriers for renal drug targeting: naproxen-lysozyme. Pharm Res 1991;8:1223-30.

16.

Largo R. , Gomez-Garre D. , Soto K. et al. Angiotensin-converting enzyme is upregulated in the proximal tubules of rats with intense proteinuria. Hypertension 1999;33:732-9.

17.

Mezzano SA , Aros CA , Droguett A. et al. Renal angiotensin II up-regulation and myofibroblast activation in human membranous nephropathy. Kidney Int Suppl 2003;(86):S39-S45.

18.

Wapstra FH , Navis GJ , Van Goor H. et al. ACE inhibition preserves heparan sulfate proteoglycans in the glomerular basement membrane of rats with established adriamycin nephropathy . Exp Nephrol 2001; 9:21-7.

19.

Bos H. , Laverman GD , Henning RH et al. Involvement of renal ACE activity in proteinuria-associated renal damage in untreated and treated adriamycin nephrotic rats. JRAAS 2003; 4:106-12.

20.

Laverman GD , Navis G. , Henning RH , de Jong PE , de Zeeuw D. Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 2002;62:1020-5.

Renal targeting of captopril using captopril-lysozyme conjugate enhances its antiproteinuric effect in adriamycin-induced nephrosis

Abstract

Keywords

Get full access to this article

References